100 related articles for article (PubMed ID: 28474339)
21. Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.
Singh N; Singh PS; Aggarwal AN; Behera D
Clin Lung Cancer; 2016 May; 17(3):205-213.e1. PubMed ID: 26589440
[TBL] [Abstract][Full Text] [Related]
22. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
[TBL] [Abstract][Full Text] [Related]
23. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
[TBL] [Abstract][Full Text] [Related]
24. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
[TBL] [Abstract][Full Text] [Related]
25. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
26. Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis.
Yin J; Wei J; Xu JH; Xiao Y; Zhang YC
Acta Haematol; 2014; 131(2):114-25. PubMed ID: 24158006
[TBL] [Abstract][Full Text] [Related]
27. [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases].
Yu YX; Shi YK; He XH; Zhou LQ; Zhou SY; Dong M; Feng FY; Sun Y
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2714-6. PubMed ID: 18167252
[TBL] [Abstract][Full Text] [Related]
28. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
29. Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center.
Huang H; Jiang Y; Wang Q; Guo L; Jin Z; Fu Z; Han Y; Sun A; Liu W; Ruan J; Wu D
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1393-1397. PubMed ID: 28478121
[TBL] [Abstract][Full Text] [Related]
30. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
31. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
Cederleuf H; Bjerregård Pedersen M; Jerkeman M; Relander T; d'Amore F; Ellin F
Br J Haematol; 2017 Sep; 178(5):739-746. PubMed ID: 28485010
[TBL] [Abstract][Full Text] [Related]
32. Comorbidity as an independent prognostic factor in elderly patients with peripheral T-cell lymphoma.
Zhao H; Wang T; Wang Y; Yu Y; Wang X; Zhao Z; Yang H; Yan B; Wu X; Da W; Zhang Y
Onco Targets Ther; 2016; 9():1795-9. PubMed ID: 27069369
[TBL] [Abstract][Full Text] [Related]
33. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.
Mehta N; Maragulia JC; Moskowitz A; Hamlin PA; Lunning MA; Moskowitz CH; Zelenetz A; Matasar MJ; Sauter C; Goldberg J; Horwitz SM
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):664-70. PubMed ID: 24035712
[TBL] [Abstract][Full Text] [Related]
34. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group.
Numata A; Miyamoto T; Ohno Y; Kamimura T; Kamezaki K; Tanimoto T; Takase K; Henzan H; Kato K; Takenaka K; Fukuda T; Harada N; Nagafuji K; Teshima T; Akashi K; Harada M; Eto T;
Bone Marrow Transplant; 2010 Feb; 45(2):311-6. PubMed ID: 19597416
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of Clinical Characteristics and Prognosis of 46 Elderly Patients with Peripheral T Cell Lymphoma (PTCL)].
Wang TT; Zhang ZG; Yang HL; Li Q; Xia B; Zhao HF; Yu Y; Wang XF; Wang YF; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):438-43. PubMed ID: 27151006
[TBL] [Abstract][Full Text] [Related]
38. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.
Hong JY; Hong ME; Choi MK; Chang W; Do IG; Jo JS; Jung SH; Park S; Kim SJ; Ko YH; Kim WS
Anticancer Res; 2015 Apr; 35(4):2465-74. PubMed ID: 25862915
[TBL] [Abstract][Full Text] [Related]
39. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma.
Zhang Y; Rose A; Khadka S; Cao B; Eatrides J; Saeed H; Shah BD; Chavez J; Bello C; Lazaryan A; Khimani F; Ibarz JP; Liu HD; Locke FL; Jain MD; Zhang L; Kharfan-Dabaja MA; Kim J; Ayala E; Nishihori T; Sokol L
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38740140
[TBL] [Abstract][Full Text] [Related]
40. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
